Abvc signs a term sheet to earn licensing fees of up to $20m and royalties of 5-12% of net sales

Fremont, ca, aug. 01, 2023 (globe newswire) -- via newmediawire -- abvc biopharma, inc. (nasdaq: abvc), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, neurology, and ophthalmology, today announced the signing of a legally binding term sheet with a prominent chinese pharmaceutical company, xinnovation therapeutics co., ltd that, subject to definitive agreements, is for the exclusive licensing of abv-1504 for major depressive disorder (mdd) and abv-1505 for attention-deficit/hyperactivity disorder in mainland china.
ABVC Ratings Summary
ABVC Quant Ranking